ViroPharma Hosts 'Teach-In' on Cytomegalovirus
July 21, 2004 17:00 ET
|
ViroPharma Incorporated
EXTON, Pa., July 21, 2004 (PRIMEZONE) -- Highlighting the great need for a well tolerated and effective treatment for cytomegalovirus (CMV), a panel of transplant clinicians and ViroPharma...
ViroPharma Announces 'Teach-In' on Cytomegalovirus Infection
July 16, 2004 09:00 ET
|
ViroPharma Incorporated
EXTON, Pa., July 16, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) announced today that the company will host a 'Teach-in' on cytomegalovirus (CMV) infection at the Plaza Hotel in New...
ViroPharma To Appeal Nasdaq Determination
June 25, 2004 17:13 ET
|
ViroPharma Incorporated
EXTON, Pa., June 25, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Incorporated Decides to Terminate Exchange Offer
June 22, 2004 08:17 ET
|
ViroPharma Incorporated
EXTON, Pa., June 22, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Incorporated Announces Base Share Amount And Auto-Conversion Price For Its Plus Cash Notes
June 17, 2004 17:57 ET
|
ViroPharma Incorporated
EXTON, Pa., June 17, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Incorporated Extends Expiration Date Until June 21, 2004
June 15, 2004 08:02 ET
|
ViroPharma Incorporated
EXTON, Pa., June 15, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Incorporated Announces Base Share Amount and Auto-Conversion Price for its Plus Cash Notes
June 09, 2004 17:11 ET
|
ViroPharma Incorporated
EXTON, Pa., June 9, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Initiates Proof of Concept Study For HCV-086 In Hepatitis C Patients
June 08, 2004 08:47 ET
|
ViroPharma Incorporated
EXTON, Pa., June 8, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the initiation of a proof of concept clinical study with HCV-086, a hepatitis C antiviral compound that...
ViroPharma Incorporated Amends Terms of Exchange Offer and Extends Expiration Date Until June 11, 2004
May 26, 2004 08:00 ET
|
ViroPharma Incorporated
EXTON, Pa., May 26, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Provides Update on Intranasal Pleconaril
May 25, 2004 09:07 ET
|
ViroPharma Incorporated
EXTON, Pa., May 25, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today provided an update on intranasal pleconaril. Schering-Plough (NYSE:SGP) has an option to enter into a license...